Bortezomib, melphalan, and prednisone (VMP) regimen for multiple Myeloma

Samantha Bryant, Dominic A. Solimando, James Waddell

Research output: Contribution to journalArticle

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Original languageEnglish (US)
Pages (from-to)25-30
Number of pages6
JournalHospital Pharmacy
Volume50
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Melphalan
Oncology
Postal Service
Prednisone
Multiple Myeloma
Pharmacists
Pharmaceutical Services
Chemotherapy
Poisons
Highway systems
Antineoplastic Agents
Drug Therapy
Neoplasms
Bortezomib
VMP regimen
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacy
  • Pharmacology
  • Pharmacology (medical)

Cite this

Bortezomib, melphalan, and prednisone (VMP) regimen for multiple Myeloma. / Bryant, Samantha; Solimando, Dominic A.; Waddell, James.

In: Hospital Pharmacy, Vol. 50, No. 1, 01.01.2015, p. 25-30.

Research output: Contribution to journalArticle

Bryant, Samantha ; Solimando, Dominic A. ; Waddell, James. / Bortezomib, melphalan, and prednisone (VMP) regimen for multiple Myeloma. In: Hospital Pharmacy. 2015 ; Vol. 50, No. 1. pp. 25-30.
@article{680397c1fc784bf58baa996d6476c703,
title = "Bortezomib, melphalan, and prednisone (VMP) regimen for multiple Myeloma",
abstract = "The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.",
author = "Samantha Bryant and Solimando, {Dominic A.} and James Waddell",
year = "2015",
month = "1",
day = "1",
doi = "10.1310/hpj5001-025",
language = "English (US)",
volume = "50",
pages = "25--30",
journal = "Hospital Pharmacy",
issn = "0018-5787",
publisher = "Facts and Comparisons",
number = "1",

}

TY - JOUR

T1 - Bortezomib, melphalan, and prednisone (VMP) regimen for multiple Myeloma

AU - Bryant, Samantha

AU - Solimando, Dominic A.

AU - Waddell, James

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

AB - The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

UR - http://www.scopus.com/inward/record.url?scp=84921271542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921271542&partnerID=8YFLogxK

U2 - 10.1310/hpj5001-025

DO - 10.1310/hpj5001-025

M3 - Article

VL - 50

SP - 25

EP - 30

JO - Hospital Pharmacy

JF - Hospital Pharmacy

SN - 0018-5787

IS - 1

ER -